Unveiling the therapeutic potential of Mondia whitei (Hook.f.) skeels in polycystic ovary syndrome via network pharmacology and molecular docking
Authors:
- 20 June 2026
- journal article
- Published by Springer Nature in In Silico Pharmacology
- Vol. 14 (2) , 166
Abstract
Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder with complex pathophysiology involving reproductive and metabolic dysfunctions. This study investigates the therapeutic potential of Mondia whitei, a traditional African medicinal plant, against PCOS using an integrative in silico approach combining network pharmacology, molecular docking, and quantitative structure-activity relationship (QSAR) modelling. Fifteen bioactive phytochemicals from M. whitei were retrieved from PubChem and prepared for docking using PyRx and OpenBabel. Target proteins APEX1 and HSP90AA1, identified via network pharmacology, were sourced from the Protein Data Bank and optimized using Schrodinger's protein preparation tools. Docking simulations revealed that 5-Chloropropacin, Yohimbine, and Loliolide exhibited strong binding affinities with APEX1, compared to the standard drug Lucanthone. For HSP90AA1, although SNX-5422 showed superior binding, Yohimbine and 5-chloropropacin demonstrated notable interactions. Hydrogen bonding and hydrophobic interactions, facilitated by key amino acid residues, contributed to the stability of these complexes when observed at 500 ns simulation. Network pharmacology analysis revealed 191 intersecting targets between M. whitei compounds and PCOS-related proteins, with HSP90AA1, APP, and PRKCA emerging as central nodes in the protein-protein interaction network. QSAR modeling, based on known inhibitors from ChEMBL, predicted pIC50 values for the best docked compounds, confirming Loliolide's have potential for druggable lead against APEX1 and Yohimbine's as druggable lead against HSP90AA1. These findings suggest that M. whitei harbours promising multi-target phytochemicals that can be tested for key proteins implicated in PCOS and this needs to be further validated experimentally for development of plant-based therapeutics. The online version contains supplementary material available at 10.1007/s40203-026-00670-z.Keywords
This publication has 28 references indexed in Scilit:
- Deciphering the Effects of Pterocarpus mildbraedii and Pterocarpus soyauxii Against Sars-CoV-2 and HIV Coinfection through the Integration of ADMET, Network Pharmacology, in silico Molecular Docking, Pharmacophore Analysis and Computational Inhibition of CDK2 and HIV-1 Viral ProteinsJournal of Computational Biophysics and Chemistry, 2026
- Why different PDB IDs for the same dysregulated protein can lead to inconsistent in-silico predictions and preclinical resultsIn Silico Research in Biomedicine, 2025
- Yohimbine as a multifunctional therapeutic agent: inhibition of lysozyme aggregation, glycation and antioxidant propertiesRSC Medicinal Chemistry, 2025
- Exploring the Effects of Pterocarpus Soyauxii Against Menopause‐Related NAFLD Based on Network Pharmacology, Molecular Docking, and Experimental ValidationChemistry & Biodiversity, 2025
- Unraveling the Role of Cathepsin B Variants in Polycystic Ovary Syndrome: Insights from a Case-Control Study and Computational AnalysesReproductive Sciences, 2025
- Pharmacological assessment of Coffea arabica compounds as potential therapeutics for cervical cancerBioinformatics Advances, 2024
- Nutritional, phytochemistry, antioxidant, and antidiabetic potentials of Hippocratea velutina (Afzel.) leaves: In vitro, ex vivo and in silico studiesPhytomedicine Plus, 2024
- Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progressArchives of Pharmacal Research, 2024
- A literature perspective on the pharmacological applications of yohimbineAnnals of Medicine, 2022
- CHARMM‐GUI: A web‐based graphical user interface for CHARMMJournal of Computational Chemistry, 2008